Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 204

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology

Open access
Rosano, Giuseppe M C, Tamargo, Juan, Kjeldsen, Keld P, Lainscak, Mitja, Agewall, Stefan, Anker, Stefan D, Ceconi, Claudio, Coats, Andrew J S, Drexel, Heinz, Filippatos, Gerasimos, Kaski, Juan Carlos, Lund, Lars, Niessner, Alexander, Ponikowski, Piotr, Savarese, Gianluigi, Schmidt, Thomas A, Seferovic, Petar, Wassmann, Sven, Walther, Thomas, Lewis, Basil S·2018·European Heart Journal - Cardiovascular Pharmacotherapy

Abstract

Renin angiotensin aldosterone system inhibitors/antagonists/blockers (RAASi) are a cornerstone in treatment of patients with cardiovascular diseases especially in those with heart failure (HF) due to their proven effect on surrogate and hard endpoints. Renin angiotensin aldosterone system inhibitors are also the basis in treatment of arterial hypertension, and they are furthermore indicated to reduce events and target organ damage in patients with diabetes and chronic kidney disease, where they have specific indication because of the evidence of benefit. Renin angiotensin aldosterone system inhibitor therapy, however, is associated with an increased risk of hyperkalaemia. Patients with chronic kidney disease and HF are at increased risk of hyperkalaemia and ∼50% of these patients experience two or more yearly recurrences. A substantial proportion of patients receiving RAASi therapy have their therapy down-titrated or more often discontinued even after a single episode of elevated potassium (K+) level. Since RAASi therapy reduces mortality and morbidity in patients with cardiovascular disease steps should, when hyperkalaemia develops, be considered to lower K+ level and enable patients to continue their RAASi therapy. The use of such measures are especially important in those patients with the most to gain from RAASi therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/ehjcvp/pvy015

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 204

Metadata

Authors
Rosano, G. M. C., Tamargo, J., Kjeldsen, K. P., Lainscak, M., Agewall, S., Anker, S. D., Ceconi, C., Coats, A. J. S., Drexel, H., Filippatos, G., Kaski, J. C., Lund, L., Niessner, A., Ponikowski, P., Savarese, G., Schmidt, T. A., Seferovic, P., Wassmann, S., Walther, T., & Lewis, B. S.
Venue
European Heart Journal - Cardiovascular Pharmacotherapy
Published
2018-05-03
Volume
4
Issue
3
Pages
180-188
ISSN
  • 2055-6837 (ISSN-L)
  • 2055-6845
OpenAlex
W2801863764
Cited by
204
References
4
FWCI
13.19
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology. https://app.cochat.ai/papers/10.1093/ehjcvp/pvy015
The paper
Rosano, G. M. C., Tamargo, J., Kjeldsen, K. P., Lainscak, M., Agewall, S., Anker, S. D., Ceconi, C., Coats, A. J. S., Drexel, H., Filippatos, G., Kaski, J. C., Lund, L., Niessner, A., Ponikowski, P., Savarese, G., Schmidt, T. A., Seferovic, P., Wassmann, S., Walther, T., & Lewis, B. S. (2018). Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology. European Heart Journal - Cardiovascular Pharmacotherapy. https://doi.org/10.1093/ehjcvp/pvy015

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.